In this article, we will examine the use of hybrid coronary revascularization to treat multivessel coronary artery disease. Coronary artery disease (CAD) is the most common cause of morbidity and mortality in the western world. The presence of multivessel CAD is associated to high short and midterm mortality and coronary artery bypass graft (CABG) is<a href="https://solaci.org/en/2023/01/12/hybrid-coronary-revascularization-a-valid-option/" title="Read more" >...</a>
There are many current randomized trials comparing percutaneous coronary intervention (PCI) with myocardial revascularization surgery (MRS) for the treatment of left main coronary artery disease (LMCAD). In the European Society of Cardiology guidelines, PCI is classified as Ia (LMCAD with low-complexity coronary disease) or IIa indication (intermediate complexity), whereas, according to the American Heart Association<a href="https://solaci.org/en/2023/01/11/real-world-revascularization-strategy-for-left-main-coronary-artery-surgery-or-pci/" title="Read more" >...</a>
Critical lower limb ischemia (CLLI) is associated with a major deterioration in quality of life and a significant increase in morbidity and mortality. Its estimated annual incidence is 220 to 3500 cases per million people, with an expected prevalence of 11% of patients with peripheral arterial disease. CLLI is the “terminal” stage of peripheral artery<a href="https://solaci.org/en/2022/11/22/best-cli-revascularization-of-critical-lower-limb-ischemia-a-pragmatic-study/" title="Read more" >...</a>
Peripheral vascular disease (PVD) has been under-studied and under-recognized in comparison with ischemic heart disease and stroke, despite its well-known impact on quality of life and its associated morbidity and mortality. According to a systematic review, it was estimated that in 2015 about 238 million people globally had PVD. This number is on the rise.<a href="https://solaci.org/en/2022/06/01/revascularization-using-des-in-infrapopliteal-disease-meta-analysis-and-change-of-paradigm/" title="Read more" >...</a>
Currently, the American and European guidelines recommend coronary angioplasty in patients with severe aortic stenosis with lesions >70% (Class IIa) who will undergo transcatheter aortic valve replacement (TAVR). However, the benefit of performing a revascularization in these patients is still uncertain. This prospective multicenter study included 2025 patients divided into two groups: complete revascularization (N = 1310)<a href="https://solaci.org/en/2022/05/24/europcr-2022-should-revascularization-be-performed-before-tavr-in-patients-with-stable-coronary-disease/" title="Read more" >...</a>
According to the STITCH and STITCHES trials, in patients with coronary artery disease and deteriorated left ventricular ejection fraction (EF), revascularization of a viable heart might reverse left ventricular systolic dysfunction. In these patients, improved EF after coronary revascularization appears to increase long term survival, particularly after cardiac artery bypass grafting (CABG), compared against medical<a href="https://solaci.org/en/2022/05/16/improved-ventricular-function-post-revascularization-fewer-events-across-subgroups/" title="Read more" >...</a>
Fractional flow reserve (FFR) has been shown effective and safe by different studies, yet not at 5 years. The aim of this multicenter registry was to assess the impact of thrombotic risk (as per CREDO-Kyoto score) as a predictor of cardiovascular events at 5 years in patients with deferred revascularization after FFR measurement. The score<a href="https://solaci.org/en/2022/04/13/5-year-tvf-and-macce-in-patients-with-deferred-of-revascularization-after-ffr-is-ffr-enough/" title="Read more" >...</a>
The COMPLETE study has shown complete revascularization in STEMI reduces cardiovascular mortality or new AMI, which generated a change in ACC/AHA 2021 revascularization guidelines. However, its impact on quality of life is yet to be studied. The aim of this prespecified analysis of the COMPLETE study is to determine whether complete revascularization improves quality of<a href="https://solaci.org/en/2022/04/05/acc-2022-complete-trial-qol-complete-revascularization-in-stemi/" title="Read more" >...</a>
Join us in the third Medtronic-SOLACI masterclass with Dr. Gregg Stone (USA) and renowned Latin-American panelists. In this last session of this cycle of 3 masterclasses organized alongside Medtronic, Dr. Stone will discuss revascularization in patients with multivessel lesions. Date: April 7th, 2022, at 07:30 p.m. (Argentina/Brazil time, UTC -3). As usual, this event is<a href="https://solaci.org/en/2022/04/05/april-7th-medtronic-solaci-masterclass-with-gregg-stone-revascularization-in-patients-with-multivessel-lesions/" title="Read more" >...</a>
Coronary artery disease is the main cause of death in patients with functioning renal transplant, reaching 30%, with the highest rate at peri transplant stage. At the same time, the incidence of acute myocardial infraction (AMI) after renal transplant ranges from 5% to 11%. This is why asymptomatic candidates are routinely screened for CAD before<a href="https://solaci.org/en/2022/03/22/is-coronary-revascularization-useful-in-renal-transplant-candidates/" title="Read more" >...</a>